Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Monday,Benzinga reports.

Pharmaceuticals announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients ...

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) have been given an average rating of “Hold” by the ...

Zentalis Pharmaceuticals LLC shares tumbled to a 52-week low this week, with the stock price touching down at $2.16. According to... ByInvesting.com • Jan 23, 2025 Zentalis stock plunges to 52 ...

In this article, we are going to take a look at where Zentalis Pharmaceuticals (NASDAQ:ZNTL) stands against other cheapest stocks that insiders are buying recently. Why should we be interested in ...

Zentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ...

(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer ...

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian ...

Stay updated on market trends for ZNTL. FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers The FDA has lifted the partial clinical ...

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...